Summary
Global Markets Direct’s, ‘Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2016’, provides an overview of the Respiratory Syncytial Virus (RSV) Infections pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus (RSV) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Respiratory Syncytial Virus (RSV) Infections and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus (RSV) Infections
- The report reviews pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Respiratory Syncytial Virus (RSV) Infections therapeutics and enlists all their major and minor projects
- The report assesses Respiratory Syncytial Virus (RSV) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Respiratory Syncytial Virus (RSV) Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus (RSV) Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Ablynx NV
ADMA Biologics, Inc.
Agilvax, Inc.
Aridis Pharmaceuticals LLC
Artificial Cell Technologies, Inc.
AstraZeneca Plc
Aviragen Therapeutics, Inc.
Bavarian Nordic A/S
Celltrion, Inc.
Codagenix, Inc.
CureVac GmbH
DBV Technologies S.A.
Emergent BioSolutions Inc.
Enanta Pharmaceuticals, Inc.
Evec, Inc.
F. Hoffmann-La Roche Ltd.
GenVec, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Globavir Biosciences, Inc.
Humabs BioMed SA
iBio, Inc.
ILiAD Biotechnologies, LLC
Ilyang Pharmaceutical Co., Ltd
Immunovaccine, Inc.
Inovio Pharmaceuticals, Inc.
Johnson & Johnson
Kineta, Inc.
mAbxience S.A.
MedImmune, LLC
Medivir AB
Merck & Co., Inc.
Mucosis B.V.
NanoBio Corporation
Navigen Pharmaceuticals, Inc.
Novavax, Inc.
Panacea Biotec Limited
Profectus BioSciences, Inc.
Pulmocide Ltd
Regeneron Pharmaceuticals, Inc.
Romark Laboratories, L.C.
Sirnaomics, Inc.
Spider Biotech
Spring Bank Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
TechnoVax, Inc.
The International Biotechnology Center (IBC) Generium
Trellis Bioscience, Inc.
Vault Pharma Inc.
Vaxart, Inc.
VaxInnate Corporation
VBI Vaccines Inc.
Virometix AG
Visterra, Inc.
VLP Biotech, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Respiratory Syncytial Virus (RSV) Infections Overview 11
Therapeutics Development 12
Pipeline Products for Respiratory Syncytial Virus (RSV) Infections - Overview 12
Pipeline Products for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis 13
Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Development by Companies 14
Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Investigation by Universities/Institutes 18
Respiratory Syncytial Virus (RSV) Infections - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Respiratory Syncytial Virus (RSV) Infections - Products under Development by Companies 22
Respiratory Syncytial Virus (RSV) Infections - Products under Investigation by Universities/Institutes 27
Respiratory Syncytial Virus (RSV) Infections - Companies Involved in Therapeutics Development 28
Ablynx NV 28
ADMA Biologics, Inc. 29
Agilvax, Inc. 30
Aridis Pharmaceuticals LLC 31
Artificial Cell Technologies, Inc. 32
AstraZeneca Plc 33
Aviragen Therapeutics, Inc. 34
Bavarian Nordic A/S 35
Celltrion, Inc. 36
Codagenix, Inc. 37
CureVac GmbH 38
DBV Technologies S.A. 39
Emergent BioSolutions Inc. 40
Enanta Pharmaceuticals, Inc. 41
Evec, Inc. 42
F. Hoffmann-La Roche Ltd. 43
GenVec, Inc. 44
Gilead Sciences, Inc. 45
GlaxoSmithKline Plc 46
Globavir Biosciences, Inc. 47
Humabs BioMed SA 48
iBio, Inc. 49
ILiAD Biotechnologies, LLC 50
Ilyang Pharmaceutical Co., Ltd 51
Immunovaccine, Inc. 52
Inovio Pharmaceuticals, Inc. 53
Johnson & Johnson 54
Kineta, Inc. 55
mAbxience S.A. 56
MedImmune, LLC 57
Medivir AB 58
Merck & Co., Inc. 59
Mucosis B.V. 60
NanoBio Corporation 61
Navigen Pharmaceuticals, Inc. 62
Novavax, Inc. 63
Panacea Biotec Limited 64
Profectus BioSciences, Inc. 65
Pulmocide Ltd 66
Regeneron Pharmaceuticals, Inc. 67
Romark Laboratories, L.C. 68
Sirnaomics, Inc. 69
Spider Biotech 70
Spring Bank Pharmaceuticals, Inc. 71
Takeda Pharmaceutical Company Limited 72
TechnoVax, Inc. 73
The International Biotechnology Center (IBC) Generium 74
Trellis Bioscience, Inc. 75
Vault Pharma Inc. 76
Vaxart, Inc. 77
VaxInnate Corporation 78
VBI Vaccines Inc. 79
Virometix AG 80
Visterra, Inc. 81
VLP Biotech, Inc. 82
Respiratory Syncytial Virus (RSV) Infections - Therapeutics Assessment 83
Assessment by Monotherapy Products 83
Assessment by Combination Products 84
Assessment by Target 85
Assessment by Mechanism of Action 87
Assessment by Route of Administration 89
Assessment by Molecule Type 91
Drug Profiles 93
(human parainfluenza virus [serotype 1] + respiratory syncytial virus) vaccine - Drug Profile 93
(influenza (virus like particle) + respiratory syncytial virus) vaccine - Drug Profile 94
AK-0529 - Drug Profile 95
ALS-8112 - Drug Profile 96
ALS-8176 - Drug Profile 97
ALX-0171 - Drug Profile 98
Antisense RNAi Oligonucleotides for RSV and Viral Respiratory Tract Infections - Drug Profile 100
AR-201 - Drug Profile 101
AZ-27 - Drug Profile 102
BTAC-585 - Drug Profile 103
danirixin - Drug Profile 104
DPX-RSV - Drug Profile 106
EV-046120 - Drug Profile 107
EV-046135 - Drug Profile 108
GBV-006 - Drug Profile 109
GNR-007 - Drug Profile 110
GSK-3003891A - Drug Profile 111
GSK-3389245A - Drug Profile 112
GV-2311 - Drug Profile 113
GXV - Drug Profile 114
influenza + RSV vaccine - Drug Profile 115
IYS-21001 - Drug Profile 116
JNJ-53718678 - Drug Profile 117
JNJ-61187165AAA - Drug Profile 118
JNJ-61187191AAA - Drug Profile 119
KIN-1400 - Drug Profile 120
MEDI-7510 - Drug Profile 121
MEDI-8897 - Drug Profile 122
Monoclonal Antibodies to Inhibit RSV-G and F Proteins for RSV Infections - Drug Profile 123
Monoclonal Antibody for Respiratory Syncytial Virus - Drug Profile 124
Monoclonal Antibody to Inhibit RSV-G and RSV-F for RSV Infections - Drug Profile 125
MPE-8 - Drug Profile 126
MV-012968 - Drug Profile 127
MVA-RSV - Drug Profile 128
nitazoxanide CR - Drug Profile 129
Oligonucleotide for respiratory syncytial virus vaccine - Drug Profile 131
Oligonucleotide for Respiratory Syncytial Virus-1 Infection - Drug Profile 132
palivizumab biosimilar - Drug Profile 133
palivizumab biosimilar - Drug Profile 134
palivizumab biosimilar - Drug Profile 135
palivizumab biosimilar - Drug Profile 136
PC-786 - Drug Profile 137
pertussis [strain BPZE1] vaccine - Drug Profile 138
presatovir - Drug Profile 140
Recombinant Protein for Respiratory Syncytial Virus - Drug Profile 141
Recombinant Protein for RSV Infections - Drug Profile 142
respiratory syncytial virus (virus like particle) vaccine - Drug Profile 143
respiratory syncytial virus (virus like particle) vaccine - Drug Profile 144
respiratory syncytial virus (virus like particle) vaccine - Drug Profile 145
respiratory syncytial virus (virus like particle) vaccines - Drug Profile 146
respiratory syncytial virus [strain 98-25147-X] vaccine - Drug Profile 147
respiratory syncytial virus vaccine - Drug Profile 148
respiratory syncytial virus vaccine - Drug Profile 149
respiratory syncytial virus vaccine - Drug Profile 152
respiratory syncytial virus vaccine - Drug Profile 153
respiratory syncytial virus vaccine - Drug Profile 154
respiratory syncytial virus vaccine - Drug Profile 155
respiratory syncytial virus vaccine - Drug Profile 156
respiratory syncytial virus vaccine - Drug Profile 157
respiratory syncytial virus vaccine - Drug Profile 158
respiratory syncytial virus vaccine - Drug Profile 159
respiratory syncytial virus vaccine - Drug Profile 160
respiratory syncytial virus vaccine - Drug Profile 161
respiratory syncytial virus vaccine - Drug Profile 162
respiratory syncytial virus vaccine - Drug Profile 163
respiratory syncytial virus vaccine - Drug Profile 164
respiratory syncytial virus vaccine - Drug Profile 165
respiratory syncytial virus vaccine - Drug Profile 166
respiratory syncytial virus vaccine - Drug Profile 167
respiratory syncytial virus vaccine - Drug Profile 168
respiratory syncytial virus vaccine - Drug Profile 169
respiratory syncytial virus vaccine - Drug Profile 170
respiratory syncytial virus vaccine - Drug Profile 171
Respiratory Syncytial Virus Vaccine - Drug Profile 172
respiratory syncytial virus vaccine - Drug Profile 173
respiratory syncytial virus vaccine - Drug Profile 174
respiratory syncytial virus vaccine 1 - Drug Profile 175
respiratory syncytial virus vaccine 1 - Drug Profile 176
respiratory syncytial virus vaccine 2 - Drug Profile 177
respiratory syncytial virus vaccine 2 - Drug Profile 178
RI-002 - Drug Profile 179
RSV-001 - Drug Profile 181
RV-521 - Drug Profile 182
SB-105-A10 - Drug Profile 183
SB-9200 - Drug Profile 185
Small Molecule for RSV - Drug Profile 187
Small Molecules for Respiratory Syncytial Virus - Drug Profile 188
Small Molecules for Respiratory Syncytial Virus Infections - Drug Profile 189
Small Molecules for RSV and Influenza A Infections - Drug Profile 190
Small Molecules for RSV Infections - Drug Profile 191
Small Molecules to Inhibit Respiratory Syncytial Virus Fusion Protein for RSV Infections - Drug Profile 192
STP-902 - Drug Profile 193
suptavumab - Drug Profile 194
SynGEM - Drug Profile 196
Synthetic Peptides to Inhibit RSV-F Protein for RSV Infection - Drug Profile 197
TRL-3D3 - Drug Profile 198
TVX-004IP - Drug Profile 199
VIS-RSV - Drug Profile 200
VMT-3 - Drug Profile 201
VPI-251 - Drug Profile 202
Respiratory Syncytial Virus (RSV) Infections - Recent Pipeline Updates 203
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects 230
Respiratory Syncytial Virus (RSV) Infections - Discontinued Products 234
Respiratory Syncytial Virus (RSV) Infections - Product Development Milestones 235
Featured News & Press Releases 235
Appendix 243
Methodology 243
Coverage 243
Secondary Research 243
Primary Research 243
Expert Panel Validation 243
Contact Us 243
Disclaimer 244
List of Tables
Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H1 2016 19
Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis, H1 2016 20
Number of Products under Development by Companies, H1 2016 21
Number of Products under Development by Companies, H1 2016 (Contd..1) 22
Number of Products under Development by Companies, H1 2016 (Contd..2) 23
Number of Products under Development by Companies, H1 2016 (Contd..3) 24
Number of Products under Investigation by Universities/Institutes, H1 2016 25
Comparative Analysis by Late Stage Development, H1 2016 26
Comparative Analysis by Clinical Stage Development, H1 2016 27
Comparative Analysis by Early Stage Development, H1 2016 28
Products under Development by Companies, H1 2016 29
Products under Development by Companies, H1 2016 (Contd..1) 30
Products under Development by Companies, H1 2016 (Contd..2) 31
Products under Development by Companies, H1 2016 (Contd..3) 32
Products under Development by Companies, H1 2016 (Contd..4) 33
Products under Investigation by Universities/Institutes, H1 2016 34
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Ablynx NV, H1 2016 35
Respiratory Syncytial Virus (RSV) Infections - Pipeline by ADMA Biologics, Inc., H1 2016 36
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Agilvax, Inc., H1 2016 37
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Aridis Pharmaceuticals LLC, H1 2016 38
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Artificial Cell Technologies, Inc., H1 2016 39
Respiratory Syncytial Virus (RSV) Infections - Pipeline by AstraZeneca Plc, H1 2016 40
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Aviragen Therapeutics, Inc., H1 2016 41
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Bavarian Nordic A/S, H1 2016 42
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Celltrion, Inc., H1 2016 43
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Codagenix, Inc., H1 2016 44
Respiratory Syncytial Virus (RSV) Infections - Pipeline by CureVac GmbH, H1 2016 45
Respiratory Syncytial Virus (RSV) Infections - Pipeline by DBV Technologies S.A., H1 2016 46
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Emergent BioSolutions Inc., H1 2016 47
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Enanta Pharmaceuticals, Inc., H1 2016 48
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Evec, Inc., H1 2016 49
Respiratory Syncytial Virus (RSV) Infections - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 50
Respiratory Syncytial Virus (RSV) Infections - Pipeline by GenVec, Inc., H1 2016 51
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Gilead Sciences, Inc., H1 2016 52
Respiratory Syncytial Virus (RSV) Infections - Pipeline by GlaxoSmithKline Plc, H1 2016 53
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Globavir Biosciences, Inc., H1 2016 54
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Humabs BioMed SA, H1 2016 55
Respiratory Syncytial Virus (RSV) Infections - Pipeline by iBio, Inc., H1 2016 56
Respiratory Syncytial Virus (RSV) Infections - Pipeline by ILiAD Biotechnologies, LLC, H1 2016 57
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Ilyang Pharmaceutical Co., Ltd, H1 2016 58
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Immunovaccine, Inc., H1 2016 59
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 60
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Johnson & Johnson, H1 2016 61
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Kineta, Inc., H1 2016 62
Respiratory Syncytial Virus (RSV) Infections - Pipeline by mAbxience S.A., H1 2016 63
Respiratory Syncytial Virus (RSV) Infections - Pipeline by MedImmune, LLC, H1 2016 64
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Medivir AB, H1 2016 65
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Merck & Co., Inc., H1 2016 66
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Mucosis B.V., H1 2016 67
Respiratory Syncytial Virus (RSV) Infections - Pipeline by NanoBio Corporation, H1 2016 68
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Navigen Pharmaceuticals, Inc., H1 2016 69
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Novavax, Inc., H1 2016 70
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Panacea Biotec Limited, H1 2016 71
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Profectus BioSciences, Inc., H1 2016 72
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Pulmocide Ltd, H1 2016 73
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 74
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Romark Laboratories, L.C., H1 2016 75
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Sirnaomics, Inc., H1 2016 76
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Spider Biotech, H1 2016 77
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2016 78
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 79
Respiratory Syncytial Virus (RSV) Infections - Pipeline by TechnoVax, Inc., H1 2016 80
Respiratory Syncytial Virus (RSV) Infections - Pipeline by The International Biotechnology Center (IBC) Generium, H1 2016 81
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Trellis Bioscience, Inc., H1 2016 82
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Vault Pharma Inc., H1 2016 83
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Vaxart, Inc., H1 2016 84
Respiratory Syncytial Virus (RSV) Infections - Pipeline by VaxInnate Corporation, H1 2016 85
Respiratory Syncytial Virus (RSV) Infections - Pipeline by VBI Vaccines Inc., H1 2016 86
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Virometix AG, H1 2016 87
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Visterra, Inc., H1 2016 88
Respiratory Syncytial Virus (RSV) Infections - Pipeline by VLP Biotech, Inc., H1 2016 89
Assessment by Monotherapy Products, H1 2016 90
Assessment by Combination Products, H1 2016 91
Number of Products by Stage and Target, H1 2016 93
Number of Products by Stage and Mechanism of Action, H1 2016 95
Number of Products by Stage and Route of Administration, H1 2016 97
Number of Products by Stage and Molecule Type, H1 2016 99
Respiratory Syncytial Virus (RSV) Infections Therapeutics - Recent Pipeline Updates, H1 2016 210
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects, H1 2016 237
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects (Contd..1), H1 2016 238
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects (Contd..2), H1 2016 239
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects (Contd..3), H1 2016 240
Respiratory Syncytial Virus (RSV) Infections - Discontinued Products, H1 2016 241
List of Figures
Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H1 2016 19
Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis, H1 2016 20
Number of Products under Development by Companies, H1 2016 21
Number of Products under Investigation by Universities/Institutes, H1 2016 25
Comparative Analysis by Clinical Stage Development, H1 2016 27
Comparative Analysis by Early Stage Products, H1 2016 28
Assessment by Monotherapy Products, H1 2016 90
Number of Products by Top 10 Targets, H1 2016 92
Number of Products by Stage and Top 10 Targets, H1 2016 92
Number of Products by Mechanism of Actions, H1 2016 94
Number of Products by Stage and Mechanism of Actions, H1 2016 94
Number of Products by Routes of Administration, H1 2016 96
Number of Products by Stage and Routes of Administration, H1 2016 96
Number of Products by Top 10 Molecule Types, H1 2016 98
Number of Products by Stage and Top 10 Molecule Types, H1 2016 98
